Corium International,Inc. (NASDAQ:CORI) Files An 8-K Other Events

ME Staff 8-k
-
0

Corium International,Inc. (NASDAQ:CORI) Files An 8-K Other Events
Item 8.01.Other Events.

On March1, 2018, Corium International,Inc. (“Corium”) issued a press release announcing the pricing of its offering of $100,000,000 aggregate principal amount of 5% Convertible Senior Notesdue 2025 (the “Notes”) to qualified institutional buyers to Rule144A under the Securities Act of 1933, as amended. Corium also granted the initial purchaser of the Notesa 13‑day option to purchase up to an additional $20,000,000 aggregate principal amount of Notes. A copy of the press release announcing the pricing of the Convertible Senior Notesis attached hereto as Exhibit99.1 and is incorporated herein by reference.

Item 8.01.Financial Statements and Exhibits.

(d)Exhibits.

Exhibit Number

Description

99.1

Press release dated March1, 2018 announcing the pricing of the Notes.


Corium International, Inc. Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 cori_Ex99_1 Exhibit 99.1 Corium Prices Offering of $100 Million of 5% Convertible Senior Notes MENLO PARK,…
To view the full exhibit click here

About Corium International,Inc. (NASDAQ:CORI)

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.